We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · May 06, 2020

Intralesional Cidofovir for Treatment of Recalcitrant Warts in Both Immunocompetent and Immunocompromised Patients

Journal of the American Academy of Dermatology

 

Additional Info

Journal of the American Academy of Dermatology
Intralesional Cidofovir for Treatment of Recalcitrant Warts in Both Immunocompetent and Immunocompromised Patients: A Retrospective Analysis of 58 Patients
J Am Acad Dermatol 2020 Apr 26;[EPub Ahead of Print], EE Anshelevich, JS Barbieri, CL Kovarik

Further Reading